So what (what this means in practice): When a field representative provides misleading information, that act is attributed upward to senior management. "We didn't know" or "the rep acted on their own" does not constitute a defense.

So why (the rationale): Without explicit upward accountability, companies can set aggressive sales targets while disclaiming responsibility for how reps meet them. Placing accountability at the management level converts compliance into an executive business risk — the only level at which organizational behavior actually changes.

So what (what this means in practice): A department that reviews its own materials and activities is not acceptable. Oversight must be structurally separated from sales functions, and then subject to a second layer of review by a committee with external perspective.

So why (the rationale): Departments with revenue targets cannot objectively assess whether their own promotional materials are compliant — the conflict of interest is structural. External committee members bring perspective that is not distorted by internal KPIs, catching the "industry drift" that insiders normalize over time.

So what (what this means in practice): Pre-use review is mandatory. There is no provision for discovering problems after materials are already in the field. Outsourcing the review process does not transfer accountability — the company retains responsibility for the approval decision.

So why (the rationale): Once a material has been distributed to healthcare professionals, recalling it does not undo the influence it has already had. Pre-use review is the only gate that can prevent problematic content from reaching clinical decision-making. Requiring sign-off at both the supervisory department and advisory committee levels creates a checkpoint that is difficult to bypass under commercial pressure.

So what (what this means in practice): Compliance with these guidelines must be embedded in how personnel are assessed. This structurally prevents a situation where sales volume is rewarded regardless of how it was achieved.

So why (the rationale): Standards that carry no consequences in performance reviews are ignored in practice. Linking compliant behavior to evaluation outcomes gives representatives and managers a concrete, career-relevant reason to apply the rules when making real-time decisions in the field.

So what (what this means in practice): Establishing a system is not enough. The company has an ongoing duty to verify what is actually happening in the field. One-time training or issuing a policy document does not satisfy this requirement.

So why (the rationale): Without monitoring, the gap between written policy and actual field behavior naturally widens over time. Continuous monitoring enables early detection and correction before problems escalate to regulatory action or patient harm.

So what (what this means in practice): Verbal briefings and informal custom are not sufficient. Both the planned approach ("how activities should be conducted") and the actual execution ("what was done") must exist in documented form.

So why (the rationale): Without records, regulators cannot reconstruct what occurred during an investigation. Documentation also forces companies to review their own activities systematically, creating an internal audit trail that supports self-correction before external scrutiny arrives.

So what (what this means in practice): Internal suppression of known problems is prohibited. Upon discovery, swift correction and prevention planning are mandatory, and proactive disclosure to regulators may be required.

So why (the rationale): Regulators cannot monitor every field interaction. If companies conceal problems, harm to clinical practice accumulates unchecked. Building a framework that actively encourages self-reporting reduces systemic risk more effectively than reactive enforcement alone.

So what (what this means in practice): Complaints from healthcare professionals are a primary signal for problems that internal monitoring may not detect. They must not be deflected — they must be treated as data for system improvement.

So why (the rationale): No headquarters team can observe every field conversation in real time. Formalizing complaints as a legitimate information channel bridges the gap between what happens in clinical settings and what management knows, ensuring the system can be corrected by those closest to the patient-care interface.

So what (what this means in practice): "We didn't do it — our contractor did" is not a defense. Responsibility for information provided about a company's product follows the product, not the organizational boundary.

So why (the rationale): Without this provision, companies could outsource problematic activities to third parties and maintain plausible deniability. Anchoring accountability to product ownership — not to who physically delivered the information — closes this structural loophole and makes the marketing authorization holder the quality controller of its entire distribution chain.